The EverFlex+ self-expanding peripheral stent system (Covidien) is the next generation of EverFlex stent technology for the treatment of peripheral arterial disease. The system strengthens Covidien’s portfolio of market leading stents used for treating the superficial femoral artery and proximal popliteal lesions. The company announced availability of the EverFlex+ in Europe from 18 January 2011.
The new EverFlex+ system is designed to reduce the risk of fracture when elongated, improving clinical outcomes for patients. The next generation system offers the same customised technology as the current EverFlex system, retaining similar radial strength and flexibility, but adds even more durability. The EverFlex family of products is engineered to provide unmatched durability in a highly flexible platform, representing a significant advance in nitinol self-expanding stent technology.
“The next generation EverFlex+ system further demonstrates our commitment to the advancement of stent technology and our goal to lead the industry in identifying and treating vascular diseases with breakthrough technologies,” said Joe Woody, president, Vascular Therapies, Covidien.
EverFlex was launched worldwide in March 2006 as the first of the “long stents” for peripheral arterial disease and stenting for the superficial femoral artery.
